339 related articles for article (PubMed ID: 25003807)
1. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII.
Derrick-Roberts AL; Pyragius CE; Kaidonis XM; Jackson MR; Anson DS; Byers S
Hum Gene Ther; 2014 Sep; 25(9):798-810. PubMed ID: 25003807
[TBL] [Abstract][Full Text] [Related]
2. Missense models [Gustm(E536A)Sly, Gustm(E536Q)Sly, and Gustm(L175F)Sly] of murine mucopolysaccharidosis type VII produced by targeted mutagenesis.
Tomatsu S; Orii KO; Vogler C; Grubb JH; Snella EM; Gutierrez MA; Dieter T; Sukegawa K; Orii T; Kondo N; Sly WS
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14982-7. PubMed ID: 12403825
[TBL] [Abstract][Full Text] [Related]
3. Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase.
Tomatsu S; Orii KO; Vogler C; Grubb JH; Snella EM; Gutierrez M; Dieter T; Holden CC; Sukegawa K; Orii T; Kondo N; Sly WS
Hum Mol Genet; 2003 May; 12(9):961-73. PubMed ID: 12700165
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII.
Bielicki J; McIntyre C; Anson DS
Mol Genet Metab; 2010 Dec; 101(4):370-82. PubMed ID: 20864369
[TBL] [Abstract][Full Text] [Related]
5. Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII.
Macsai CE; Derrick-Roberts AL; Ding X; Zarrinkalam KH; McIntyre C; Anderson PH; Anson DS; Byers S
Mol Genet Metab; 2012 Jun; 106(2):202-13. PubMed ID: 22525091
[TBL] [Abstract][Full Text] [Related]
6. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice.
Elliger SS; Elliger CA; Lang C; Watson GL
Mol Ther; 2002 May; 5(5 Pt 1):617-26. PubMed ID: 11991753
[TBL] [Abstract][Full Text] [Related]
7. Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice.
Sly WS; Vogler C; Grubb JH; Zhou M; Jiang J; Zhou XY; Tomatsu S; Bi Y; Snella EM
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2205-10. PubMed ID: 11226217
[TBL] [Abstract][Full Text] [Related]
8. Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy.
Derrick-Roberts AL; Panir K; Pyragius CE; Zarrinkalam KH; Atkins GJ; Byers S
Mol Genet Metab; 2016 Nov; 119(3):249-257. PubMed ID: 27692945
[TBL] [Abstract][Full Text] [Related]
9. A novel model of murine mucopolysaccharidosis type VII due to an intracisternal a particle element transposition into the beta-glucuronidase gene: clinical and pathologic findings.
Vogler C; Levy B; Galvin N; Sands MS; Birkenmeier EH; Sly WS; Barker J
Pediatr Res; 2001 Mar; 49(3):342-8. PubMed ID: 11228259
[TBL] [Abstract][Full Text] [Related]
10. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus.
Watson GL; Sayles JN; Chen C; Elliger SS; Elliger CA; Raju NR; Kurtzman GJ; Podsakoff GM
Gene Ther; 1998 Dec; 5(12):1642-9. PubMed ID: 10023443
[TBL] [Abstract][Full Text] [Related]
11. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.
Vogler C; Sands MS; Galvin N; Levy B; Thorpe C; Barker J; Sly WS
J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337
[TBL] [Abstract][Full Text] [Related]
12. Gene transfer of low levels of beta-glucuronidase corrects hepatic lysosomal storage in a large animal model of mucopolysaccharidosis VII.
Wolfe JH; Sands MS; Harel N; Weil MA; Parente MK; Polesky AC; Reilly JJ; Hasson C; Weimelt S; Haskins ME
Mol Ther; 2000 Dec; 2(6):552-61. PubMed ID: 11124056
[TBL] [Abstract][Full Text] [Related]
13. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells.
Ross CJ; Bastedo L; Maier SA; Sands MS; Chang PL
Hum Gene Ther; 2000 Oct; 11(15):2117-27. PubMed ID: 11044913
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy.
Xu L; Mango RL; Sands MS; Haskins ME; Ellinwood NM; Ponder KP
Mol Ther; 2002 Dec; 6(6):745-58. PubMed ID: 12498771
[TBL] [Abstract][Full Text] [Related]
16. Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.
Cadaoas J; Boyle G; Jungles S; Cullen S; Vellard M; Grubb JH; Jurecka A; Sly W; Kakkis E
Mol Genet Metab; 2020 May; 130(1):65-76. PubMed ID: 32192868
[TBL] [Abstract][Full Text] [Related]
17. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors.
Stein CS; Kang Y; Sauter SL; Townsend K; Staber P; Derksen TA; Martins I; Qian J; Davidson BL; McCray PB
Mol Ther; 2001 Jun; 3(6):850-6. PubMed ID: 11407898
[TBL] [Abstract][Full Text] [Related]
18. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse.
Sferra TJ; Backstrom K; Wang C; Rennard R; Miller M; Hu Y
Mol Ther; 2004 Sep; 10(3):478-91. PubMed ID: 15336648
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy for murine mucopolysaccharidosis type VII.
Sands MS; Vogler C; Kyle JW; Grubb JH; Levy B; Galvin N; Sly WS; Birkenmeier EH
J Clin Invest; 1994 Jun; 93(6):2324-31. PubMed ID: 8200966
[TBL] [Abstract][Full Text] [Related]
20. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery.
Richard M; Arfi A; Seguin J; Gandolphe C; Scherman D
Gene Ther; 2009 Jun; 16(6):746-56. PubMed ID: 19357715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
